Erytech pivots to extracellular vesicle drug delivery

This Week

Nov 23, 2022

Jazz plays coda to blood cancer approval, securing FDA nod for revised dosing schedule

SpaceX, ISS partner to test remote control of drug delivery technology on orbiting laboratory

Erytech pivots to extracellular vesicle drug delivery after lead candidate collapses

ScPharmaceuticals prices $50M offering to fund commercialization of on-body infusor

The Top Line Podcast: don’t miss out on the newest episode where we discuss ASCO data, rising health tech stars, and more. Listen now.

 

Featured

Jazz plays coda to blood cancer approval, securing FDA nod for revised dosing schedule

Jazz Pharmaceuticals has won FDA approval for a revised dosing schedule for its blood cancer therapy Rylaze, giving physicians the option to prescribe intramuscular doses of the drug on Monday, Wednesday and Friday.
 

Top Stories

SpaceX, ISS partner to test remote control of drug delivery technology on orbiting laboratory

The International Space Station National Laboratory is sponsoring another study of drug delivery in the thermosphere, partnering with Houston Methodist Research Institute and SpaceX to test a system in a model orbiting Earth.

Erytech pivots to extracellular vesicle drug delivery after lead candidate collapses

Erytech is stepping up its focus on the drug delivery applications of its preclinical extracellular vesicles, pivoting toward the platform after halting development of its lead asset in the wake of a phase 3 flop.

ScPharmaceuticals prices $50M offering to fund commercialization of on-body infusor

ScPharmaceuticals has secured funding for commercialization of its recently approved on-body infusor, pricing a $50 million public offering ahead of the planned launch of the product early next year.

With Arcutis' steroid-free cream off to the races in plaque psoriasis, company pads case for eczema expansion

Arcutis' roflumilast cream 0.15%—a lower dose than the 0.3% formulation approved in late July as Zoryve—aced its primary endpoint and all secondary endpoints in a phase 3 study in patients 6 and older with mild to moderate atopic dermatitis.

Kindeva links up with former Pfizer unit Meridian to form drug-device CDMO specialist

Kindeva will merge with ex-Pfizer subsidiary Meridian Medical Technologies to spawn a globetrotting drug-device contract development and manufacturing organization. Both companies have been in the drug delivery game for decades, but Meridian's reputation took a hit after multiple EpiPen entanglements.
 
Fierce podcasts

Don't miss an episode

'The Top Line': Celebrating the Fiercest Women in Life Sciences

This week on “The Top Line,” we share this week's headlines and discuss the 2022 honorees in our annual Fiercest Women in Life Sciences report.

 

Resources

Podcast

Medscape Medical Affairs Thought Leaders in Medical Affairs

How can Medical Affairs divisions bring greater value to their organizations and practitioners every day?
eBook

Using Digital Therapies and Patient Engagement to Improve Clinical Outcomes

See how digital therapeutics (DTx) combined with patient engagement software offer a new opportunity for life science organizations (LSOs) to better serve and support patients. Download the guide from Health Catalyst to learn more.
Whitepaper

THE BIODRUG REVOLUTION

Accelerating bioproduction towards high performance and scale
Whitepaper

EHR vs Registry Data for RWE – Heart Failure as a Case Study

Electronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs?
Whitepaper

Navigating the Data Deluge: Turning Data Into Insight Across the Health Care and Life Sciences Industries

Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem.

Whitepaper

The Most Suitable Dosage Form Technologies for the Oral Delivery of Lipid-Based Formulations

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?
Research

Versatility of Softgel Technology - Encapsulation of a Volatile Compound

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.
Whitepaper

Lipid-Based Drug Delivery System to Bring Poorly Soluble Drugs to Market

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?
Webinar

The Faster Path From Pre-Filled Syringe to Auto-Injector

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.

Whitepaper

Formulation Strategies When Transitioning From Vial to PFS

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

Whitepaper

Softgel Formulation Enables Oral Delivery of Testosterone

Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy.

Whitepaper

Strategies for the Optimal Scale-up & Tech Transfer of Oral Small Molecules

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.